Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.
Compugen Ltd (symbol: CGEN) is a cutting-edge drug discovery company specializing in developing therapeutic proteins and monoclonal antibodies to meet critical needs in immunology and oncology. By leveraging a sophisticated infrastructure of proprietary scientific insights, predictive platforms, algorithms, and machine learning systems, Compugen excels in in silico (computer-based) prediction and selection of promising product candidates for its pipeline program.
Compugen's business model is robust and diversified, encompassing partnerships and collaborations for the further development and commercialization of its product candidates. These collaborations typically offer milestone payments and royalties on product sales, providing Compugen with multiple revenue streams. The company's U.S. subsidiary, based in South San Francisco, focuses on developing monoclonal antibodies.
At the core of Compugen's operations is its clinical-stage therapeutic discovery and development efforts, primarily in cancer immunotherapy. Its comprehensive immuno-oncology pipeline includes four clinical-stage programs, each targeting immune checkpoints discovered through computational methods. Notable programs include COM701, COM902, and bapotulimab. These programs are designed to tackle various mechanisms of immune resistance, with a particular focus on myeloid targets.
Recent achievements highlight Compugen's forward momentum. The company announced it would release its fourth quarter and full-year 2023 financial results on March 5, 2024. Compugen's President and CEO, Anat Cohen-Dayag, emphasized the company's strong financial footing, collaboration successes, and the anticipated catalytic milestones in 2024.
Key partnerships enhance Compugen’s clinical progress. For instance, the company has a license agreement with Gilead Sciences for COM503, a first-in-class antibody program against IL-18 binding protein. This agreement includes a $60 million upfront payment and a $30 million milestone payment upon IND clearance.
Another significant partnership is with AstraZeneca, which is advancing a PD-1/TIGIT bispecific antibody derived from Compugen's COM902 into Phase 3 development. This program, rilvegostomig, targets biliary tract cancer and nonsquamous non-small cell lung cancer. These collaborations underscore the extensive potential and validation of Compugen's computational discovery platform.
Compugen's financial health is robust, with a reported cash balance of $101.3 million as of March 31, 2024, ensuring operational funding into 2027. The company has demonstrated prudent financial management, achieving net revenues and reducing operational losses over time.
Headquartered in Israel, with additional offices in San Francisco, Compugen is listed on both Nasdaq and the Tel Aviv Stock Exchange, making it a prominent player in the biotech sector. For investors and stakeholders, Compugen represents a beacon of innovation and potential in cancer immunotherapy.
Compugen Ltd. (Nasdaq: CGEN) has announced that it will present new clinical data regarding its candidate COM701 during the upcoming American Society of Clinical Oncology (ASCO) annual meeting from June 2-6, 2023, in Chicago. The data will focus on the triple combination therapy of COM701, BMS-986207 (anti-TIGIT), and nivolumab in patients with metastatic endometrial cancer. The presentation titled Preliminary antitumor activity of the combination of COM701 + BMS-986207 + nivolumab is scheduled for June 5, 2023. This research highlights Compugen's commitment to innovative cancer immunotherapy methods.
Company Background: Compugen is advancing several therapeutic programs, including COM902 and the partnered program rilvegostomig, with a focus on addressing immune resistance in cancer treatments.
Compugen Ltd. (Nasdaq: CGEN) announced the upcoming presentation of pre-clinical data on its lead asset, COM503, at the 20th CIMT Annual Meeting in Mainz, Germany, from May 3-5, 2023. COM503 is a first-in-class anti-IL18 binding protein antibody designed to inhibit cancer growth by releasing endogenous IL-18, which is crucial for activating NK and T cells in the tumor microenvironment. The company's plan includes filing an IND for COM503 in 2024.
The presentation, featuring high-affinity interactions of COM503 with IL-18 binding protein, aims to demonstrate enhanced anti-tumor activity while preserving peripheral immunity. Compugen's research highlights the potential of targeting cytokine biology in cancer treatment and positions COM503 as a transformative candidate within its broader immuno-oncology pipeline.
Compugen Ltd. (NASDAQ: CGEN) announced its upcoming presentation at the AACR annual meeting from April 14-19, 2023, in Orlando, Florida. The research focuses on the correction of the GENCODE gene model, which enables accurate detection of the novel target PVRIG. This advancement aims to enhance cancer immunotherapy research. Dr. Anat Cohen-Dayag emphasized the importance of single cell technology in understanding cancer biology. The presentation is scheduled for April 18, 2023, and will explore algorithms for gene model correction impacting PVRIG and TIGIT pathways. Compugen is advancing its product candidates, COM701 and COM902, targeting solid tumors.
Compugen Ltd. (Nasdaq: CGEN) will participate in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023, at 10:00 AM ET. The event will be held virtually, and interested parties can access a live webcast through the Investor Relations section of Compugen's website. A replay will be available for 90 days post-event. Compugen is focused on developing cancer immunotherapies, with notable candidates including COM701 and COM902. The company is headquartered in Israel and also has a presence in San Francisco, CA.
Compugen Ltd. (NASDAQ: CGEN) announced the dosing of the first patient in a proof-of-concept study evaluating a triple combination of COM701, COM902, and pembrolizumab for metastatic microsatellite stable colorectal cancer (MSS CRC). This follow-up to previous positive findings aims to assess the treatment's efficacy in patients with liver metastases who have undergone up to three lines of therapy. Initial findings are expected by the end of 2023. The study is based on earlier Phase 1 data showing anti-tumor activity with the dual combination of COM701 and nivolumab. Compugen continues to advance its immunotherapy pipeline with promising candidates.
Compugen Ltd. (CGEN) reported its financial results for Q4 and full-year 2022, highlighting significant progress in clinical studies, including upcoming triple combination studies targeting metastatic microsatellite stable colorectal cancer (MSS CRC) and platinum-resistant ovarian cancer (PROC). The company has approximately $83.7 million in cash, expected to fund operations through 2024. Revenues for Q4 were $7.5 million, increasing from $6 million in 2021. Total net loss for the year was $33.7 million. Notably, AstraZeneca's advancement of a related program triggered a $7.5 million milestone payment, validating Compugen's pipeline.
Compugen Ltd. (NASDAQ: CGEN) announced that AstraZeneca's bi-specific antibody, rilvegostomig, derived from Compugen's COM902, is set to progress into a Phase 3 trial in 2023. This trial will evaluate rilvegostomig's effectiveness as a PD-1/TIGIT bi-specific therapeutic. AstraZeneca is also expanding its Phase 2 program across various cancer indications. Compugen has received $10 million upfront and $15.5 million in milestone payments from AstraZeneca and is eligible for up to $200 million in additional milestones along with tiered royalties on future sales.
Compugen Ltd. (NASDAQ: CGEN) has announced a scheduled release of its fourth quarter and full year 2022 financial results on February 27, 2023, before the U.S. markets open. The management will conduct a conference call and webcast at 8:30 AM ET to discuss the results and provide a corporate update. Interested parties can join the call via telephone or access the live webcast on the company's website. Compugen, based in Israel, specializes in cancer immunotherapy and predictive computational discovery, with product candidates COM701 and COM902 targeting solid tumors, and a partnered program with AstraZeneca in Phase 2 development.
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company, announced its upcoming presentation at the SVB Securities Global Biopharma Conference on February 16, 2023, at 9:20 AM ET. The event will be held virtually, and a live webcast will be accessible through the Investor Relations section of Compugen's website, with a replay available afterward.
Compugen is pioneering computational target discovery for cancer immunotherapies, with product candidates like COM701 and COM902. The company also has a partnered program, AZD2936, in Phase 2 development by AstraZeneca.
Compugen Ltd. (NASDAQ: CGEN) announced its participation in the JMP Securities C-Suite Series, scheduled for January 30, 2023, at 11:00 am ET. CEO Anat Cohen-Dayag and other management team members will discuss the company's advancements in the DNAM-1 axis. A live webcast of the event will be available on Compugen's Investor Relations webpage, with a replay accessible afterward. Compugen specializes in cancer immunotherapies and has developed several promising product candidates, including COM701 and COM902 for solid tumors, with ongoing collaborations such as the AZD2936 program with AstraZeneca.
FAQ
What is the current stock price of Compugen (CGEN)?
What is the market cap of Compugen (CGEN)?
What is Compugen Ltd's primary business focus?
What makes Compugen unique in the biotech industry?
Who are Compugen's key partners?
What are some of Compugen's notable products?
What recent financial milestones has Compugen achieved?
Where is Compugen Ltd headquartered?
On which stock exchanges are Compugen's shares listed?
What are some of Compugen's recent achievements?
What is the significance of Compugen’s computational discovery platform?
What is Compugen's approach to advancing its pipeline?
